Unknown

Dataset Information

0

Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo.


ABSTRACT: Chimeric antigen receptor (CAR)-modified T cells are endowed with novel antigen specificity and are most often administered to patients without an engineered mechanism to control the CAR T cells once infused. "Suicide switches" such as the small molecule-controlled, inducible caspase-9 (iCas9) system afford the ability to selectively eliminate engineered T cells; however, these approaches are designed for all-or-none, irreversible termination of an ongoing immune response. In order to permit reversible and adjustable modulation, we have created a CAR that is capable of on-demand downregulation by fusing the CAR to a previously developed ligand-induced degradation (LID) domain. Addition of a small molecule ligand triggers exposure of a cryptic degron within the LID domain, resulting in proteasomal degradation of the CAR-LID fusion protein and loss of CAR on the surface of T cells. This fusion construct allowed for reversible and "tunable" inhibition of CAR T cell activity in vitro. Delivery of the triggering molecule in CAR-LID-treated tumor-bearing mice temporarily reduced CAR activity through modulation of CAR surface expression. The ability to more flexibly modulate CAR T cell expression through a small molecule provides a platform for controlling possible adverse side effects, as well as preclinical investigations of CAR T cell biology.

SUBMITTER: Richman SA 

PROVIDER: S-EPMC7335755 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5963729 | biostudies-literature
| S-EPMC7441178 | biostudies-literature
| S-EPMC6813558 | biostudies-literature
| S-EPMC5428208 | biostudies-literature
| S-EPMC5716148 | biostudies-literature
| S-EPMC2174455 | biostudies-literature
| S-EPMC2747535 | biostudies-other
| S-EPMC4751072 | biostudies-literature
| S-EPMC3967004 | biostudies-literature
| S-EPMC6160382 | biostudies-literature